Andrew Lumsden Purchases 100,000 Shares of PolyNovo (ASX:PNV) Stock

PolyNovo Limited (ASX:PNV) insider Andrew Lumsden bought 100,000 shares of PolyNovo stock in a transaction dated Tuesday, February 24th. The stock was acquired at an average price of A$0.91 per share, with a total value of A$91,400.00.

PolyNovo Price Performance

The company has a debt-to-equity ratio of 38.17, a quick ratio of 1.58 and a current ratio of 3.03. The stock has a market capitalization of $645.94 million, a P/E ratio of 65.37, a P/E/G ratio of 2.63 and a beta of 1.67.

About PolyNovo

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.